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Abstract  
Oxaliplatin and carboplatin are two platinum(II) drugs in widespread clinical use for the 
treatment of various types of cancers; yet, structural information on their interactions with 
proteins is scarce. Here, the X-ray structures of the adducts formed upon reaction of carboplatin 
and oxaliplatin with bovine pancreatic ribonuclease (RNase A) are reported and compared with 
results obtained for the structure of the RNase A-cisplatin adduct derived from isomorphous 
crystals, under the same experimental conditions. Additional details on the binding mode of 
these metallodrugs toward RNase A are provided by Electrospray Ionisation Mass Spectrometry 
(ESI MS) measurements, thus offering insight on the occurring metal-protein interactions. 
Notably, while carboplatin and cisplatin mainly bind the side chain of Met29, oxaliplatin also 
binds the side chains of Asp14, of catalytically important His119 and, to a lesser extent, of 
His105. On the basis of the available data, a likely mechanism for oxaliplatin hydrolysis and 
binding to the protein is proposed. These results are potentially useful for a better understanding 
of the biological chemistry, toxicity and side effects of this important class of antitumor agents. 
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1. Introduction 
Cisplatin (cis-diamminedichloroplatinum(II), Figure 1) is one of the most potent anticancer drugs 
in established clinical use for the treatment of several kinds of cancer [1-2]. Carboplatin and 
oxaliplatin (Figure 1) are two cisplatin analogs that are widely used in cancer therapeutics either 
as an alternative to cisplatin (carboplatin) or for cancer types that are poorly responsive to 
cisplatin (oxaliplatin) [3-5]. Apparently, these metallodrugs exert their effects mainly by 
interfering with the DNA replication and transcription machinery through formation of adducts 
with nuclear DNA; however their specific pharmacological profiles appear to be quite distinct 
[6-7]. Beyond their mechanistically relevant DNA interactions, cisplatin, carboplatin and 
oxaliplatin (Figure 1) have been implicated in extensive formation of Pt-protein adducts. Though 
the involvement of these adducts in the mode of action and toxicity of Pt drugs is still unclear, 
more and more attention is being placed upon protein-Pt drugs interactions in relation to their 
overall pharmacological and toxicological impact [8-11]. Yet, the structural information 
concerning the interactions of platinum drugs with proteins and the characterization of the 
resulting adducts is quite limited [8-11]. In particular, while the interaction between cisplatin and 
proteins is underscored by a number of biochemical, biophysical and structural studies [12-20], 
the formation of oxaliplatin and carboplatin-protein adducts is far less explored and understood 
[21-24]. 
 
Figure 1 
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From the crystallographic point of view, formation of complexes between cisplatin and hen egg 
white lysozyme (HEWL) [12], the copper chaperone Atox-1 [13], bovine erythrocyte Cu, Zn 
superoxide dismutase (beSOD) [14], bovine pancreatic ribonuclease (RNase A) [15], human 
superoxide dismutase [16], horse heart cytochrome c [17], Na+/K+-ATPase [18] and human 
serum albumin [19] has been studied. On the other hand, the only structures known for the other 
two Pt drugs are those of their adducts with HEWL [21-24].  
The structure of the main adduct that forms when cisplatin reacts with RNase A was recently 
reported [15]. This structure, which was refined at 1.85 Ǻ resolution in the space group C2, 
presents two molecules in the asymmetric unit (molecule A and B). The Pt(II) center is bound to 
the protein in a slightly distorted square-planar arrangement and is able to form monodentate or 
bidentate adducts. In particular, Pt(II) can bind either to Met29 (molecule A) or to Met29 and 
Gln28 simultaneously (molecule B) (Figure 2A). An additional structure for RNase A-cisplatin 
adduct (space group P3221), obtained upon crystallizing purified protein after 24 h of incubation 
in the presence of a large excess of cisplatin, shows that additional binding sites can be observed 
close to His105 and His119 [25]. 
RNase A was chosen as a model to study protein interactions with Pt-based [15, 20, 25, 26] and 
other metal drugs [27-28], since it is a stable, small, well characterized protein that is 
commercially available at low cost; in addition, it is easy to crystallize, forming crystals resistant 
to soaking under different experimental conditions. This protein is frequently used as a model 
system also in many other fields, including protein chemistry, enzymology, chemical synthesis 
and structural biology [29]. 
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Here, we report the X-ray structures of the complexes formed when oxaliplatin or carboplatin 
react with RNase A. Structural data are nicely supported by independent Electrospray Ionisation 
Mass Spectrometry (ESI MS) measurements. Thanks to the present data, crystal structures are 
now available for the derivatives of the same protein with the three main platinum drugs. These 
structures were obtained from isomorphous crystals with two molecules in the asymmetric unit 
and under the same experimental conditions. Accordingly, direct structural comparisons can be 
done that are meaningful and instructive and may contribute to understand the molecular basis 
for the relevant differences in their respective pharmacological profiles. 
 
2. Materials and Methods 
2.1   Crystallization 
Oxaliplatin, carboplatin and RNase A (type XII-A), sodium citrate and PEG4K were obtained 
from Sigma. Crystals of the RNase A adducts were obtained by soaking experiments where pre-
grown monoclinic protein crystals were incubated with an excess of the platinum drug (at a 
protein to platinum ratio 1:10). This procedure has been already used to obtain crystals of 
productive complexes of RNase A including that with cisplatin [15] and other metallodrugs [26-
28]. Briefly, the crystals of RNase A were grown as previously described [15,26-28] by hanging-
drop vapor mixing 1 µL of RNase A at 20 mg mL-1 with equal volumes of reservoir solution 
containing 20% PEG4000 and 20 mM sodium citrate buffer pH 5.0 at 298 K. Two weeks after 
their appearance, crystals have been soaked for four days in a solution of carboplatin or 
oxaliplatin dissolved in 10 µL of reservoir. Final Pt drugs:protein concentration ratios were 10:1. 
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2.2   Data collection and refinement 
X-ray diffraction data have been collected from single crystals at the CNR Institute of 
Biostructure and Bioimages, Naples, Italy, using a Saturn944 CCD detector equipped with CuKα 
X-ray radiation from a Rigaku Micromax 007 HF generator. Crystals have been flash-frozen at 
100 K using nitrogen gas produced by an Oxford Cryosystem (and maintained at 100 K during 
the data collection) without using cryoprotectants, following the dehydration procedure [30] 
already used in many other works [31-33]. Data sets were processed and scaled using the 
HKL2000 package [34].  Although the soaking significantly affects the quality and the 
diffraction power of RNase A crystals, X-ray diffraction data have been collected at 2.09 Å and 
2.27 Å resolution for carboplatin and oxaliplatin, respectively. Attempts to improve the 
resolution collecting datasets on crystals soaked with Pt drug with a reduced time of soaking (up 
to 5 hours) leads to acquisition of data corresponding to ligand-free RNase A. Data collection 
statistics are reported in Table S1. The structures have been solved by molecular replacement 
method, using the PDB file 1JVT [35], without water molecules and ligands, as starting model. 
The refinement was carried out with Refmac5 [36], model building and map inspections were 
performed using Coot [37]. 5% of the data was used for calculation of the R-free value. The 
initial 2Fo-Fc and Fo-Fc electron density maps clearly indicated the position of Pt ions. The 
binding of Carboplatin induces the disordering of residues 16-22 and of the Tyr25 side chains, 
which are not included in the final model. The binding of Oxaliplatin induces disordering of 
residues 16-23 in molecule A, 18-21 in molecule B and of Gln28 side chain. In this last structure 
residues 16-23 in molecule A and residues 18-19 in molecule B have been omitted from the final 
model, the other disordered residues (residues 16-17 and 20-21 of molecule B) are fitted in a 
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poor electron density Refinement statistics are reported in Table S1. Structure validation has 
been carried out using Procheck [38]. Coordinates and structure factors for the adducts have been 
deposited in the Protein Data Bank (PDB codes 4S0Q and 4S18). 
 
2.3 Electrospray mass spectrometry 
A solution of Cisplatin, carboplatin or oxaliplatin with RNase A (10-4 M) (3:1 metal/protein 
ratio) in 20 mmol L-1 ammonium acetate pH 6.8 was incubated at 37°C for one week and ESI 
MS spectra were recorded after 24, 72 h and one week. After a 20-fold dilution with water, ESI 
MS spectra have been recorded by direct introduction at 5 μl min-1 flow rate in an Orbitrap high-
resolution mass spectrometer (Thermo, San Jose, CA, USA), equipped with a conventional ESI 
source. The working conditions were the following: spray voltage 3.1 kV, capillary voltage 45 V, 
capillary temperature 220°C, tube lens voltage 230 V. The sheath and the auxiliary gases were 
set, respectively, at 17 (arbitrary units) and 1 (arbitrary units). For acquisition, Xcalibur 2.0. 
software (Thermo) was used and monoisotopic and average deconvoluted masses were obtained 
by using the integrated -Xtract tool. For spectrum acquisition, a nominal resolution (at m/z 400) 
of 100,000 was used. 
 
3. Results 
3.1 Crystal structures 
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The structures of RNase A-carboplatin and RNase A-oxaliplatin have been solved at 2.09 and 
2.27 Ǻ resolution, respectively. The overall structures of the two adducts are reported in Figure 2 
B and 2C. The structures have been refined to Rfactor=20.5 and 22.4 (Rfree=26.2 and 30.1), for 
the RNase A complexes with carboplatin and oxaliplatin, respectively. In both structures, the 
electron density maps of protein regions are rather well defined, with exceptions consisting of a 
few portions in both the molecules present in the asymmetric unit (molecule A and B, hereafter) 
of the two complexes. Similarly to what found for the RNase A-cisplatin complex [15] (Figure 
2A), in both RNase A-carboplatin and RNase A-oxaliplatin adducts platination does not affect 
the overall conformation of the protein, which remains very similar to the wild-type (CA root 
mean square deviations in the range 0.36-0.60 Å). 
 
Figure 2 
 
As previously found for cisplatin [15] and chloroplatinite (PtCl4
2−) [20], the RNase A-
carboplatin interaction in both A and B molecules mainly occurs at the SD atom of the side chain 
of Met29. However, due to unclear electron density maps likely associated with low occupancy 
and to the possible conformational disorder of this site, the local environment of the bound Pt(II) 
center, in the RNase A-carboplatin adduct, could not be unambiguously determined (Figure 3A 
and B). The refinement of B-factors of Pt ligands and the inspection of residual Fo-Fc electron 
density maps suggests that the Pt ions have occupancy= 0.50 and 0.35 for molecule A and B, 
respectively. In both these chains, platination of Met29 induces a disordering of residue 16-22 
and of Tyr25 side chain.  
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Figure 3 
 
Although crystals of RNase A-oxaliplatin diffract to a resolution slightly lower than that 
obtained for RNase A-carboplatin and RNase A-cisplatin [15] complexes, the electron density 
maps clearly reveal details of the binding. In the RNase A-oxaliplatin structure, six Pt binding 
sites have been identified, i.e. three binding sites for each molecule of the asymmetric unit. 
In the main oxaliplatin binding site, the Pt(II) ion is bound to ND1 atom of His119 (Figure 4A 
and B). In this site, the electron density map is well defined and clearly shows that oxaliplatin 
retains the [dach] ligand upon binding to the protein. A water molecule complete the 
coordination sphere of the Pt centre. Retention of the dach ligand of oxaliplatin is observed 
during binding to model peptides in other studies [39]. These results are also in line with the 
experimental observation by Shoeib and coworkers that β-alanyl-L-histidine dipeptide 
(carnosine) is able to bind oxaliplatin inhibiting its cytotoxic action [39]. Notably, the occupancy 
factor for the oxaliplatin fragment is = 0.8 in both A and B chains, but its orientation is different 
in the two molecules: indeed, the dach moiety is exposed to the solvent in molecule A, whereas it 
orients toward the active site in molecule B. In both cases, an extensive network of hydrogen 
bonds stabilizes the binding. 
Figure 4 
 
In the second binding site (Figure 4C and D), the Pt(II) ion is coordinated to SD atom of Met29, 
as for RNase A-cisplatin [15] and RNase A-carboplatin adducts. Furthermore, in both molecules 
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A and B, beyond the SD atom of Met29, Pt also coordinates to OD2 atom of Asp14. Residual 
Fo-Fc electron density map in this site indicates a possible variability in the anchoring mode of 
oxaliplatin also close to Met29 and Asp14 side chains. Platination induces a disordering of 
residues 16-23 in molecule A and 18-21 in molecule B. The occupancy factor for the oxaliplatin 
fragment (Figure 4C and D) in this site is = 0.4 in molecule A and = 0.6 in molecule B. The 
relatively low occupancy of the oxaliplatin fragment in molecule A does not allow the modelling 
of the dach moiety (Figure 4C). 
Finally, a minor binding site has been observed close to His105 (Figure 4 E and F). In this site 
only the Pt atom with occupancy = 0.20 has been modelled.  
 
3.2 ESI MS measurements 
A further  validation of the proposed RNase A-Pt ligation patterns and of the above interpretation 
of the electron density maps was achieved by performing independent ESI MS  measurements on 
Pt drug-protein adducts according to the established experimental procedure developed in our 
laboratory (see Materials and Methods section) (Figure 5). ESI MS spectra were recorded for 
RNase A-oxaliplatin (Figure 5A), RNase A-carboplatin (Figure 5B), and also for RNase A-
cisplatin adducts (Figure 5C).  
Inspection of mass spectrometry results provides evidence for the formation of a variety of Pt 
adducts of different nature, in considerable amounts. 
In all cases, monometalated adducts are preferentially formed, though appreciable amounts of bis 
metalated derivatives are seen, especially in the case of oxaliplatin.  
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Oxaliplatin forms, at first, two kinds of derivatives, of mass 13988.3 and 14078.3 Da, in 
comparable amounts, assignable respectively to bidentate and monodentate species (Figure 5A); 
with time, the relative abundance of the bidentate adduct become higher and predominant on 
monodentate adduct, with associated release of oxalate ligand. In analogy with oxaliplatin, 
carboplatin (Figure 5B), first, forms a predominant monodentate derivative; for longer 
incubation times the cyclobutane-1,1-dicarboxylate ligand (CBD) is progressively released and a 
peak assignable to the bidentate adduct increases in intensity. Though of low intensity, a peak 
falling at 14423.4 Da, is representative for bis-adduct formation.    
Comparative analysis of peak intensities for the metal-protein adducts suggests that oxaliplatin 
and cisplatin (Figure 5C) are far more reactive than carboplatin, although differing ionization 
efficiencies may also be a contributing factor. 
 
Figure 5 
 
4. Discussion  
We have reported here the X-ray structures of the RNase A-carboplatin and RNase A-oxaliplatin 
adducts. As the crystal structure of the RNase A-cisplatin had been previously solved [15], we 
are in the fortunate position that structures are now available for RNase A adducts with the three 
main Pt drugs; this allows making instructive structural comparisons. Notably, such an analysis 
is carried out using structures obtained by soaking metallodrugs into pre-existing isomorphous 
RNase A crystals grown under very similar conditions. The finding that the RNase A crystals 
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contain two molecules in the asymmetric unit adds an internal validation to our results. 
Moreover, the crystallographic investigation has been nicely complemented by ESI MS data on 
the same adducts which support the correct identification of the Pt species bound to the protein. 
The importance of using two independent biophysical methods such as X-ray crystallography 
and ESI MS on the same system is thus further documented [41-42] and underscored. In 
particular, ESI MS data turn very valuable in elucidating the nature of protein bound platinum 
fragments for the RNase A-carboplatin adduct where crystallographic data are ambiguous, 
whereas X-ray diffraction data add molecular details on the binding of oxaliplatin to the protein. 
The results of this comparative structural analysis are summarized in Table 1. On the basis of the 
reported data, the following considerations can be done: 
-cisplatin and carboplatin behave in a similar way, as they both produce, under the applied 
experimental conditions, a monometalated protein derivative where the Pt ion of the drug 
fragment mainly coordinates to SD atom of Met29. The platinum fragment coordinated to Met29 
is distinct for the two drugs: it is [Pt(NH3)2]
2+ for cisplatin and [Pt(NH3)2CBD] for carboplatin. 
Analyzing the metal binding site of carboplatin and cisplatin in detail, minor differences are 
observed that are probably due to the different steric hindrance of the Pt ligands. In the molecule 
B of the RNase A-cisplatin adduct [15], Pt can coordinate both SD atom of Met29 and NE atom 
of Gln28 (bidentate interaction)[15], whereas only a monodentate interaction with Met29 seems 
to occur for carboplatin. Notably, ESI MS results performed after a long incubation time point 
out that the CBD ligand may be released, so that a type of Pt fragment identical to that arising 
from cisplatin is eventually associated with the protein, and that a dimetalated adduct can also be 
formed. In addition, it must be stressed that cisplatin shows a greater reactivity than carboplatin 
in terms of amounts of formed derivatives as well witnessed by ESI MS results.  
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Table 1 
   
Oxaliplatin also binds Met29, but it coordinates RNase A through interaction of a [Ptdach]2+ 
fragment. Furthermore, a bidentate coordination is observed that involves the OD1 atom of 
Asp14. The result confirms previous observations obtained with HEWL in which coordination of 
the [Ptdach]2+ cation selectively occurs at the level of the free carboxylate group of Asp residues 
[24]. ESI MS data suggest that the binding of oxaliplatin to the protein could occur according to 
a two-step process. Combining our data with the mechanism proposed for the acid hydrolysis of 
oxaliplatin [43-44], a picture of the RNase A-oxaliplatin recognition can be drawn: the oxalate 
ligand of Pt is detached in two consecutive steps, which involve the formation of oxalate 
monodentate complex. The ring-opening step allows the replacement of oxalate with the 
carboxylate from the Asp residue (Figure 6). Ring-opened Met adducts of carboplatin have been 
studied previously [45]. Since the formation of hydrolysis product species has been observed in 
vivo [43-44], this mechanism could be operative also under physiological conditions. 
 
 
Figure 6 
 
Notably, in the RNase A-oxaliplatin adduct, other Pt binding sites are also detected. In the main 
binding site, Pt coordinates the ND1 atom of His119. Furthermore, oxaliplatin can also bind, 
with low occupancy, the NE2 atom of His105. These results are interesting since it has been 
previously shown, by studying its interaction with HEWL, that oxaliplatin preferentially binds 
 15 
Asp side chains [24], while both carboplatin and cisplatin show a preference for His side chains 
[12, 46]. This is even more surprising if one takes into account that the oxaliplatin fragment 
bound to RNase A is larger than those of carboplatin and cisplatin. These results could be 
explained by considering the kinetics of the protein-metallodrug recognition. In fact, it has been 
shown that, contrary to its DNA binding capacity, the rate of protein binding of oxaliplatin may 
be significantly higher than that of cisplatin and carboplatin [7, 47]. On the other hand, these data 
also agree with previous crystallographic findings on the adduct formed in the reaction between 
trans-Pt derivatives and RNase A [26]. It should be also noted that cisplatin has been found to 
bind both His105 and His119 in RNase A-cisplatin crystals of a different space group and 
obtained under different crystallization conditions [25]. In this respect, we cannot exclude that 
carboplatin could be able to bind His105 and His119, using the approach described in reference 
25 or after longer soaking time. 
 
5. Conclusions 
The results of this comparative structural analysis suggest that cisplatin and carboplatin behave 
similarly when they react with proteins, while oxaliplatin shows a significantly different 
behavior. We suggest that differences in reactivity and adduct formation with proteins, which 
could be related to a different kinetics of metallodrug-protein binding, may have a more general 
significance and may be at the basis of the different pharmacological and toxicological profile of 
the three drugs. Altogether these data support previous hypotheses that metal ligands play a key 
role in the protein-metallodrug interactions, driving the drug-biological target recognition and 
stabilizing the structure of the final adduct [48]. The binding of cisplatin, carboplatin and 
oxaliplatin to Met appears also interesting if one considers that Pt binding to S-donor ligands, 
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including methionine and glutathione, occur in physiological conditions and that it plays a 
relevant role in the Pt-drugs metabolism. S-donor binding of Pt-drugs was suggested to be 
involved as an intermediate in transport to the DNA in nucleus [48-51]. Finally, our data point 
out that the three Pt drugs mainly bind proteins through formation of monodentate (like 
carboplatin or cisplatin in molecule A [15]) or bidentate (like oxaliplatin, or cisplatin in molecule 
B [15]) derivatives.  
Before binding, the Pt complex needs to be activated. Activation consists of the release of labile 
ligands: two chlorides in the case cisplatin, the cyclobutandicarboxylate ligand in the case of 
carboplatin; oxalate in the case of oxaliplatin. The activation process and the consequent protein 
metalation may manifest a large kinetic variability depending on the nature of the leaving group 
and on the possible “assistance” offered by the protein. 
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Table 1. Structural features of Pt-drug binding sites from the X-ray structures of the adducts 
obtained by soaking procedure on C2 crystals of RNase A and by ESI MS data 
Pt drug RNase A binding sites as 
revealed by X-ray 
structural analysis of the 
adducts obtained by 
soaking procedure* 
Number of 
binding sites 
Binding mode 
suggested by X-
ray structural 
analysis 
Drug Fragment 
suggested by X-
ray structural 
analysis 
Drug Fragment as 
revealed by ESI 
MS  
 
Cisplatin** 
Mol A:   Met29 
 
Mol B: Met29, Gln28 
1 monodentate  
 
bidentate  
[Pt(NH3)H2O]2+ 
 
[Pt(NH3)2]2+ 
 
[Pt(NH3)Cl]+ 
[Pt(NH3)2]2+ 
 
carboplatin 
 
Mol A:   Met29 
 
Mol B:   Met29 
1 monodentate  
 
monodentate  
undefined 
 
undefined 
 
 
[Pt(NH3)2]2+ 
[Pt(NH3)2CBD] 
2[Pt(NH3)2CBD] 
oxaliplatin 
 
Mol A:   His119 
               Met29, Asp14 
               His105 
 
 
Mol B:   His119 
               Met29, Asp14 
               His105 
3 monodentate  
bidentate  
monodentate 
 
 
monodentate  
bidentate  
monodentate 
[Pt(dach)(H2O)]2+ 
[Pt(dach)]2+ 
undefined 
 
 
[Pt(dach)(H2O)]2+ 
[Pt(dach)]2+ 
undefined 
 
Oxaliplatin 
 
[Pt(dach)]2+ 
 
Oxaliplatin 
+[Pt(dach)]2+ 
 
2[Pt(dach)]2+ 
 
 
*It is interesting to note that all RNase A residues involved in the three platinated adducts 
(Asp14, Gln28, Met29, His105 and His119) are conserved in the human pancreatic enzyme (HP-
RNase). 
**from reference 15 
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Figure legends 
Figure 1. Structure of cisplatin, carboplatin and oxaliplatin 
Figure 2. Ribbon representation of the asymmetric unit of the RNase A-cisplatin (panel A), 
RNase A-oxaliplatin (panel B) and RNase A-carboplatin (panel C) structures. The molecules A 
and B are coloured in cyan and purple, respectively. Side chains of residues involved in the Pt 
drugs recognition are shown along with Pt centres. In panel B and C, 2Fo-Fc electron density 
maps are coloured in red and contoured at 4σ. The structures of RNase A-oxaliplatin and RNase 
A-carboplatin have been deposited in the Protein Data Bank with entry codes 4S18 and  4S0Q. 
The structure of RNase A-cisplatin was already solved and deposited in the PDB with entry code 
4OT4. 
 
Figure 3. Details of the binding sites of Pt(II) in the RNase A-Carboplatin adduct. Pt ion is 
bound to Met29 in the molecule A (panel A) and B (panel B). Asp14 side chain is included in the 
figure, since it is involved in the recognition of oxaliplatin (see below). 2Fo-Fc electron density 
maps are contoured at 0.8σ level (grey) and 4.0σ level (red). 
 
Figure 4. Details of the binding sites of Pt(II) in the RNase A-oxaliplatin structure. The drug is 
bound to protein through a coordinative interaction with side chain of His119 (panel A and B for 
molecules A and B, respectively). The [Ptdach]2+ fragment is involved in a number of hydrogen 
bonding interactions with water molecules that form an intricate network stabilizing the 
structure. Furthermore, Pt ion is bound to Met29 and Asp14 side chains (panel C and D for 
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molecules A and B, respectively). Oxaliplatin binding to sulfur atoms of physiologically 
important molecules like glutathione has been already observed in other studies [39]. Finally, a 
minor Pt binding site has been identified close to side chain of His105 (panel E and F for 
molecules A and B, respectively). 2Fo-Fc electron density maps are contoured at 0.8σ level 
(grey) and 4.0σ level (red). Molecule A is coloured in cyan and molecule B in purple. In panels 
C, E and F only the atoms included in the final models are reported, for this reason in panel C 
some atoms of dach fragment are omitted, whereas in panels E and F only the Pt atoms are 
reported. 
 
Figure 5. Deconvoluted ESI MS spectra of RNase A treated respectively with 3*10-4 M of 
oxaliplatin (panel A), carboplatin (panel B) and cisplatin, (CDDP, panel C) recorded after 24h 
(A), 72h (B), 168h (C) of incubation at 37 °C. Experimental conditions: Metal:protein ratio = 
3:1; buffer: 20 mM ammonium acetate pH 6.8. 
 
Figure 6. Proposed mechanism for oxaliplatin hydrolysis and binding to Met29 and Asp14 
residues of RNase A. The bidentate adduct formation proceeds through ring opening and initial 
formation of a monodentate intermediate. 
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A 
B  
 27 
C  
Figure 2. Ribbon representation of the asymmetric unit of the RNase A-cisplatin (panel A), 
RNase A-oxaliplatin (panel B) and RNase A-carboplatin (panel B) structures. The molecules A 
and B are coloured in cyan and purple, respectively. Side chains of residues involved in the Pt 
drugs recognition are shown along with Pt centres. In panel B and C, 2Fo-Fc electron density 
maps are coloured in red and contoured at 4σ. The structures of RNase A-oxaliplatin and RNase 
A-carboplatin have been deposited in the Protein Data Bank with entry codes 4S18 and 4S0Q. 
The structure of RNase A-cisplatin was already solved and deposited in the PDB with entry code 
4OT4. 
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A B  
Figure 3. Details of the binding sites of Pt(II) in the RNase A-Carboplatin adduct. Pt ion is 
bound to Met29 in the molecule A (panel A) and B (panel B). Asp14 side chain is included in the 
figure, since it is involved in the recognition of oxaliplatin (see below). 2Fo-Fc electron density 
maps are contoured at 0.8σ level (grey) and 4.0σ level (red). 
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E F  
Figure 4. Details of the binding sites of Pt(II) in the RNase A-oxaliplatin structure. The drug is 
bound to protein through a coordinative interaction with side chain of His119 (panel A and B for 
molecules A and B, respectively). The [Ptdach]2+ fragment is involved in a number of hydrogen 
bonding interactions with water molecules that form an intricate network stabilizing the 
structure. Furthermore, Pt ion is bound to Met29 and Asp14 side chains (panel C and D for 
molecules A and B, respectively). Oxaliplatin binding to sulfur atoms of physiologically 
important molecules like glutathione has been already observed in other studies [39]. Finally, a 
minor Pt binding site has been identified close to side chain of His105 (panel E and F for 
molecules A and B, respectively). 2Fo-Fc electron density maps are contoured at 0.8σ level 
(grey) and 4.0σ level (red). Molecule A is coloured in cyan and molecule B in purple. In panels 
C, E and F only the atoms included in the final models are reported, for this reason in panel C 
some atoms of dach fragment are omitted, whereas in panels E and F only the Pt atoms are 
reported. 
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Figure 5. Deconvoluted ESI MS spectra of RNase A treated respectively with 3*10-4 M of 
oxaliplatin (panel A), carboplatin (panel B) and cisplatin, (CDDP, panel C) recorded after 24h 
(A), 72h (B), 168h (C) of incubation at 37 °C. Experimental conditions: Metal:protein ratio = 
3:1; buffer: 20 mM ammonium acetate pH 6.8.  
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Figure 6. Proposed mechanism for oxaliplatin hydrolysis and binding to Met29 and Asp14 
residues of RNase A. The bidentate adduct formation proceeds through ring opening and initial 
formation of a monodentate intermediate.  
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